Compare, Analyse Jubilant Pharmova with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT PHARMOVA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the worlds leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industrys broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 JUBILANT PHARMOVA    MYLAN
EQUITY SHARE DATA
    JUBILANT PHARMOVA
Mar-19
MYLAN
Dec-18
JUBILANT PHARMOVA /
MYLAN
5-Yr Chart
Click to enlarge
High Rs8983,490-   
Low Rs6181,921-   
Sales per share (Unadj.) Rs572.01,605.9-  
Earnings per share (Unadj.) Rs36.243.6-  
Cash flow per share (Unadj.) Rs59.5344.3-  
Dividends per share (Unadj.) Rs4.500-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs301.91,737.3-  
Shares outstanding (eoy) m159.28514.50-   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.31.7 78.6%   
Avg P/E ratio x20.962.0 33.7%  
P/CF ratio (eoy) x12.77.9 162.0%  
Price / Book Value ratio x2.51.6 161.2%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m120,6941,391,984 8.7%   
No. of employees `0002.435.0 6.8%   
Total wages/salary Rs m19,2600-   
Avg. sales/employee Rs Th38,120.623,606.9 161.5%   
Avg. wages/employee Rs Th8,058.40-   
Avg. net profit/employee Rs Th2,414.3641.0 376.6%   
INCOME DATA
Net Sales Rs m91,108826,243 11.0%  
Other income Rs m3570-   
Total revenues Rs m91,466826,243 11.1%   
Gross profit Rs m17,390213,801 8.1%  
Depreciation Rs m3,709154,705 2.4%   
Interest Rs m2,19839,739 5.5%   
Profit before tax Rs m11,84019,356 61.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,8020-   
Tax Rs m3,268-3,079 -106.1%   
Profit after tax Rs m5,77022,436 25.7%  
Gross profit margin %19.125.9 73.8%  
Effective tax rate %27.6-15.9 -173.5%   
Net profit margin %6.32.7 233.2%  
BALANCE SHEET DATA
Current assets Rs m45,848461,373 9.9%   
Current liabilities Rs m20,897336,392 6.2%   
Net working cap to sales %27.415.1 181.0%  
Current ratio x2.21.4 160.0%  
Inventory Days Days5784 68.0%  
Debtors Days Days5193 54.6%  
Net fixed assets Rs m65,498160,278 40.9%   
Share capital Rs m159440 36.2%   
"Free" reserves Rs m47,9300-   
Net worth Rs m48,089893,844 5.4%   
Long term debt Rs m42,429964,745 4.4%   
Total assets Rs m114,6852,397,637 4.8%  
Interest coverage x6.41.5 429.5%   
Debt to equity ratio x0.91.1 81.7%  
Sales to assets ratio x0.80.3 230.5%   
Return on assets %6.92.6 267.9%  
Return on equity %12.02.5 478.0%  
Return on capital %12.43.2 390.4%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-4,8050-   
CASH FLOW
From Operations Rs m11,215171,693 6.5%  
From Investments Rs m-10,118-88,747 11.4%  
From Financial Activity Rs m6,574-79,985 -8.2%  
Net Cashflow Rs m7,6121,422 535.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 73.32 Rs / USD

Compare JUBILANT PHARMOVA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare JUBILANT PHARMOVA With: NEULAND LABS  GLENMARK PHARMA  CIPLA  J.B.CHEMICALS  PFIZER  



Today's Market

Sensex Ends 179 Points Lower; Tata Steel and Adani Ports Among Top Nifty Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views On News

Jubilant Pharmova Drops 6% on Weak March Quarter Numbers (Views On News)

Jun 8, 2021

Here's a rundown on the latest quarterly results of Jubilant Pharmova.

Points to Keep in Mind Before Subscribing to Krishna Institute of Medical Sciences' IPO (Views On News)

Jun 15, 2021

All you need to know about the IPO of Krishna Institute of Medical Sciences.

Why Did Shares of Divi's Lab Rally Today? (Views On News)

Jun 10, 2021

The stock jumped 3.6% in intraday trade to hit its 52-week high.

Laurus Labs Hits New Life High. Up 500%+ in One Year (Views On News)

Jun 8, 2021

Laurus Labs trades higher for the eight straight day, soars 73% in 3 months.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

More Views on News

Most Popular

Hotel Stocks Will Reward Investors (Fast Profits Daily)

Jun 8, 2021

This is why I'm bullish on the hotel and hospitality sector.

My 'Unlock' Investments (Fast Profits Daily)

Jun 11, 2021

The best unlock investments you can make in the market.

The Most Visible Sign of India's Revival is on Two Wheels (Profit Hunter)

Jun 9, 2021

Investing in the best stocks could result in wealth compounding on a massive scale.

How I Discovered a 400-Year-Old Open Secret to Extreme Wealth (Profit Hunter)

Jun 11, 2021

Charlie Munger's open secret about investing success.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

JUBILANT PHARMOVA SHARE PRICE


Jun 17, 2021 (Close)

TRACK JUBILANT PHARMOVA

  • Track your investment in JUBILANT PHARMOVA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT PHARMOVA

JUBILANT PHARMOVA 5-YR ANALYSIS

COMPARE JUBILANT PHARMOVA WITH

FEATURED VIDEOS

The 3-Word Secret to Earning Incredible Returns

Buy & Hold v/s In & Out Investing

An Investing System that Found 20 Winners in a Row

Top Pick for Next Decade

More Featured Videos

MARKET STATS